secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-056658
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata receives FDA Fast Track for AP-SA02 phage therapy for S. aureus bacteremia
--------------------------------------------------------------------------------

- Fast Track designation enables rolling BLA review and potential Accelerated Approval and Priority Review.
- Phase 3 superiority study anticipated to begin in H2 2026.
- AP-SA02 targets complicated bacteremia from MSSA and MRSA.
- FDA designation underscores unmet need in severe, often deadly S. aureus infections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926056658/0001104659-26-056658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926056658/tm2613773d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer